Search | Clinical Trials Finder

Conditions: COPD
Interventions: Indacaterol, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 93
States / cities: Homewood, Alabama • Jasper, Alabama • Phoenix, Arizona + 83 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Not listed
Lead sponsor: VA New York Harbor Healthcare System; Federal
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions: Dental Cleaning, Dental Plaque sampling; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: COPD, Early-Onset
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 30 Years to 55 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Chronic Graft Versus Host Disease
Interventions: Axatilimab, Biospecimen Collection, Questionnaire Administration, Skin Biopsy, Skin Measurement; Biological · Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Tampa, Florida • Boston, Massachusetts • Seattle, Washington

Conditions: Diabetes, Cholesterol, Cancer, Blood Pressure Disorders, Heart Disease, Respiratory Ilness, COPD, Adverse Drug Reaction (ADR), Poly Pharmacy
Interventions: Not listed
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Bryan, Texas

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: alpha-1 proteinase inhibitor (human); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more

Conditions: Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions: Care Coordination; Behavioral
Lead sponsor: Mathematica Policy Research, Inc.; Other
Eligibility: Not listed
Enrollment: 18,277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 15
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Deer Park, California + 16 more

Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions: Semaglutide Pen Injector; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions: Silicone Stent Airway Implant; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Asthma
Interventions: Intervention: Budesonide, Usual care: albuterol + systemic steroids; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COPD
Interventions: SpiroPD; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 55 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: COPD, Cystic Fibrosis, Asthma, Healthy
Interventions: Hyperpolarized Helium-3; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 5 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 74
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more

Conditions: COPD
Interventions: EPIC (Empower People to Independence in COPD), Usual Care; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions: Roflumilast, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 2,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 217
States / cities: Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more

Conditions: Pulmonary Disease, Chronic Obstructive, Hypercapnia, Hypoxia
Interventions: Humidified nasal high flow with oxygen; Device
Lead sponsor: Temple University; Other
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
Interventions: Alvelestat (MPH966), Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COPD, Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

AMBULATORY OXIMETRY MONITORING (AOM): a New Approach to Quantify Oxygen Desaturation in Ambulatory COPD Patients

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

SPIROMICS Study of Early COPD Progression (SOURCE)

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

Evaluation of Programs of Coordinated Care and Disease Management

Tiotropium (Spiriva) Rehabilitation Study

Feasibility of Semaglutide in Advanced Lung Disease

Evaluating the Clinical Effectiveness of 3D Printing for a Patient-specific Silicone Stent Airway Implant

Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department

Feasibility of At-Home Handheld Spirometry

Acute Exacerbation of COPD and Physical Activity - Preliminary Study

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

Vascular Subphenotypes of Lung Disease in HIV & COPD

High Resolution Micro OCT Imaging

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Nurse Coach-Led Early Palliative Care for Older Adults With COPD and Their Care Partners: The Project EPIC Pilot RCT

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry